Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
crispr/cas9 plasmid, c32-447 (1 trial)
talen (1 trial)
Neoplasms (Phase 1)
Trials (1 total)
Trial APIs (2 total)